[12] Patent
[11] Patent No.:GC0009382  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141742
Date of the Decision to Grant the Patent:17/Dec/2018

[21] Application No.:GC 2015-28809

[22] Filing Date:22/1/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
24/1/2014
61/931,090

[72] Inventors:1- Hans, Roland LÖNN،2- Stephen CONNOLLY،3- John Fritiof PONTÉN،4- Staffan PO KARLSSON،5- Nicholas PALMER،6- Steven SWALLOW،7- Carl-Johan AURELL،8- Kevin DOYLE،9- Amanda VAN DE POËL،10- Graham JONES،11- David WATSON،12- Jaqueline MACRITCHIE

[73] Owner: AstraZeneca AB, SE -151, 85 , Sodertalje , Sweden

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/553; A61P 11/00; C07D 209/34, 213/84, 215/227, 241/44, 261/20, 263/58, 265/36, 267/10, 277/68, 279/16, 333/38, 413/12 (2006.01)

[56] Cited Documents:

-WO 2010/128324 Al (ASTRAZENECA AB [SE] ; ASTRAZENECA UK LTD [GB] ; FORD RH ONAN [GB]; METE A) 11 November 2010
-WO 2009/074829 Al (ASTRAZENECA AB [SE] ; ASTRAZENECA UK LTD [GB] ; CAGE PETER ALAN [PT] ; FU) 18 June 2009
-WO 2011/154677 Al (ASTRAZENECA AB [SE] ; ASTRAZENECA UK LTD [GB] ; FORD RH ONAN [GB]; KI NCHI) 15 December 2011
 
Examiner: PH. Neda J. AlMuallem

[54] CERTAIN 2S-N-[1S-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
[57] Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD) , to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
No. of claims: 11     No. of figures: 5


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.